- Home
- PDD vs GILD Comparison
PDD vs GILD Comparison
Compare PDD & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDD | GILD |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0B | 147.6B |
| IPO Year | 2018 | 1992 |
Fundamental Metrics
Financial Performance| Metric | PDD | GILD |
|---|---|---|
| Price | $104.98 | $121.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 20 |
| Target Price | ★ $134.30 | $127.10 |
| AVG Volume (30 Days) | ★ 8.2M | 7.1M |
| Earning Date | 11-18-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 2.66% |
| EPS Growth | N/A | ★ 6514.05 |
| EPS | ★ 9.68 | 6.42 |
| Revenue | ★ $58,790,822,784.00 | $29,087,000,000.00 |
| Revenue This Year | $10.73 | $3.63 |
| Revenue Next Year | $14.94 | $2.97 |
| P/E Ratio | ★ $11.26 | $18.49 |
| Revenue Growth | ★ 12.48 | 2.79 |
| 52 Week Low | $87.11 | $88.57 |
| 52 Week High | $139.41 | $128.70 |
Technical Indicators
Market Signals| Indicator | PDD | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 19.87 | 49.40 |
| Support Level | $114.89 | $118.17 |
| Resistance Level | $119.00 | $123.74 |
| Average True Range (ATR) | 2.42 | 2.76 |
| MACD | -0.64 | -0.54 |
| Stochastic Oscillator | 1.92 | 38.84 |
Price Performance
Historical ComparisonAbout PDD PDD Holdings Inc.
PDD Holdings operates commerce businesses in over 80 countries globally. Its main operations are Pinduoduo, a social commerce platform in China, and Temu, a global e-commerce marketplace. PDD also has a community group purchase business in China. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).